People

Renowned fund manager and buyside analyst joins investor relations and strategic communications specialists

According to the resolution of the Annual General Meeting in BioArctic AB (publ) on May 15, 2018 the members of the Nomination Committee for the 2019 Annual General Meeting shall be appointed through a procedure where the three largest shareholders in terms of voting power according to Euroclear’s transcription of the share register as of September 30, 2018 are contacted by the Chairman of the Board and asked to appoint one representative each to the Nomination Committee.

Joint expertise to help tackle potential problems ranging from disease outbreaks to bioterrorism

Novartis has been on something of a housecleaning binge since Vasant (Vas) Narasimhan took over the chief executive officer position from Joseph Jimenez in January of this year. On October 30, Novartis indicated it planned to abandon approximately 20 percent of its research projects.

It has been a busy month for San Francisco-based Nektar Therapeutics. It started with a partnership to pair its lead drug candidate with one developed by pharma giant Pfizer. On Wednesday, the company named a Genentech veteran to helm its oncology programs.

Theranos fit in with the opaque culture of Silicon Valley, which allowed it to thrive and amass a fortune without delivering anything, book argues.

CellGeni is pleased to announce the appointment of Dr. Udo Nirenberg as Vice President of Quality Management and member of the management team.

Nouscom announced today that it has appointed John F. McDonald as an independent director to its Board of Directors.

Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments designed to transform bone marrow transplantation for the treatment of blood diseases, announces that Andrew Wright has been appointed as Financial Controller & Company Secretary, a non-Board position, and that Lawrence Pemble, Chief Operating Officer, will step down from the Board, both with immediate effect.

MMS Holdings Inc. (MMS) - an award-winning, data-focused CRO - announced that one of its leader’s in programming and data sciences, Chris Hurley, has been asked and has accepted a second three-year term as Americas Director of PhUSE - an independent, global organization for more than 8,000 data managers, biostatisticians, clinical programmers, and eClinical IT professionals.